Shidong Jia, MD, PhD, is the Founder and CEO of Predicine. Prior to founding Predicine, Shidong spearheaded the oncology biomarker strategies and drug & diagnostics co-development at Genentech. His previous work identified p110beta as novel drug target for PTEN-deficient tumors, a finding that laid the foundation for clinical development and testing of p110beta inhibitors in cancers. He previously held various senior research positions focusing on translational and clinical cancer research at Novartis Institutes for BioMedical Research and Harvard University. Shidong was awarded the P.A.R.T. Investigatorship Award from the Dana-Farber Cancer Institute. Shidong holds a MD and PhD from Harbin Medical University and Peking Union Medical College, and completed postdoctoral training at the Dana Farber Cancer Institute – Harvard University.
Liquid Biopsy Showcase: Predicine
Predicine is a molecular insights company that has developed a ctDNA+ctRNA combo liquid biopsy test to provide a comprehensive understanding of the molecular alterations in cancer. Through its CLIA/CAP facilities in the US and China, Predicine partners with leading biopharma companies and hospitals to support global clinical trials, targeted therapy, and early cancer detection.
Transforming Immuno-Oncology With ctRNA + ctDNA Liquid Biopsy Solutions
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer patients. This talk will focus on the development and clinical applications of circulating RNA and DNA-based liquid biopsy tests in biomarker-driven clinical trials.